Mylan NV (MYL)

17.88
0.03 0.17
NASDAQ : Health Technology
Prev Close 17.91
Open 17.83
Day Low/High 17.62 / 17.94
52 Wk Low/High 16.63 / 39.59
Volume 3.78M
Avg Volume 7.36M
Exchange NASDAQ
Shares Outstanding 515.47M
Market Cap 9.50B
EPS 0.70
P/E Ratio 39.21
Div & Yield N.A. (N.A)

Latest News

Theravance Biopharma And Mylan Expand YUPELRI® (revefenacin) Development And Commercialization Agreement To Include China And Adjacent Territories

Theravance Biopharma And Mylan Expand YUPELRI® (revefenacin) Development And Commercialization Agreement To Include China And Adjacent Territories

First and only once-daily, nebulized bronchodilator has potential to address unmet needs of China's nearly 100 million chronic obstructive pulmonary disease (COPD) patients

Theravance Biopharma And Mylan Expand YUPELRI® (revefenacin) Development And Commercialization Agreement To Include China And Adjacent Territories

Theravance Biopharma And Mylan Expand YUPELRI® (revefenacin) Development And Commercialization Agreement To Include China And Adjacent Territories

First and only once-daily, nebulized bronchodilator has potential to address unmet needs of China's nearly 100 million chronic obstructive pulmonary disease (COPD) patients

Theravance Biopharma And Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis At The 2019 ATS International Conference

Theravance Biopharma And Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis At The 2019 ATS International Conference

Post-Hoc Analysis Highlights the Potential Role of YUPELRI in the COPD Treatment Paradigm

Theravance Biopharma And Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis At The 2019 ATS International Conference

Theravance Biopharma And Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis At The 2019 ATS International Conference

Post-Hoc Analysis Highlights the Potential Role of YUPELRI in the COPD Treatment Paradigm

Mylan To Host Investor Day On July 31, 2019 In New York City

Mylan To Host Investor Day On July 31, 2019 In New York City

HERTFORDSHIRE, England and PITTSBURGH, May 17, 2019 /PRNewswire/ --  Mylan N.V.

Mylan And Biocon To Present Final Overall Survival Data For Ogivri™ (trastuzumab-dkst), A Biosimilar To Herceptin®, At The American Society Of Clinical Oncology (ASCO) Annual Meeting

Mylan And Biocon To Present Final Overall Survival Data For Ogivri™ (trastuzumab-dkst), A Biosimilar To Herceptin®, At The American Society Of Clinical Oncology (ASCO) Annual Meeting

Ogivri™ is the first biosimilar for Herceptin® approved by the U.S. Food and Drug Administration (FDA) for all indications including HER2-positive breast and gastric cancers

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Attorneys general from 44 states allege the nation's largest generic drugmakers conspired to artificially inflate and manipulate prices for more than 100 different generic drugs.

Stock Selloff, Trade War, Teva, Take-Two and Oil Prices - 5 Things You Must Know

Stock Selloff, Trade War, Teva, Take-Two and Oil Prices - 5 Things You Must Know

U.S. stock futures fall sharply after China vows to stand its ground in the escalating trade war with the United States; oil prices surge after Saudi Arabia alleges two of its tankers were victims of a 'sabotage attack,' Teva and other drugmakers are alleged to have conspired to artificially inflate and manipulate prices for generic drugs.

Mylan Expands Oncology Portfolio With Launch Of Generic Tarceva® Tablets

Mylan Expands Oncology Portfolio With Launch Of Generic Tarceva® Tablets

Erlotinib Hydrochloride Tablets treat metastatic non-small cell lung and pancreatic cancers

Mylan To Present At The 2019 Bank Of America Merrill Lynch Healthcare Conference

Mylan To Present At The 2019 Bank Of America Merrill Lynch Healthcare Conference

HERTFORDSHIRE, England and PITTSBURGH, May 10, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan Tanks After First-Quarter Revenue Misses Estimates

Mylan Tanks After First-Quarter Revenue Misses Estimates

Mylan sinks after the company reports first-quarter revenue that misses analysts' expectations.

Mylan Reports First Quarter 2019 Results And Reaffirms 2019 Guidance

Mylan Reports First Quarter 2019 Results And Reaffirms 2019 Guidance

HERTFORDSHIRE, England and PITTSBURGH, May 7, 2019 /PRNewswire/ -- Mylan N.V.

Global Stocks Drift As China Confirms Trade Participation, US Warns on Tariffs

Global Stocks Drift As China Confirms Trade Participation, US Warns on Tariffs

Global stocks were mixed higher Tuesday, while U.S. equity futures drifted modestly into the red, as investors kept risk appetite in check ahead of a key series of trade talks between Washington and Beijing later this week that could define or collapse an elusive pact between the world's two largest economies.

Mylan Expected to Earn 79 Cents a Share

Mylan Expected to Earn 79 Cents a Share

Mylan revenue expected to rise 1.6% to $2.7 billion.

Mylan To Release First Quarter 2019 Financial Results On May 7, 2019

Mylan To Release First Quarter 2019 Financial Results On May 7, 2019

HERTFORDSHIRE, England, and PITTSBURGH, April 26, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Striving To Create Better Health For A Better World: Mylan's Global Social Responsibility 2018 Progress Report Now Available

Striving To Create Better Health For A Better World: Mylan's Global Social Responsibility 2018 Progress Report Now Available

HERTFORDSHIRE, England and PITTSBURGH, April 3, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan Institutional LLC Initiates Voluntary Nationwide Recall Of Levoleucovorin Injection Due To The Presence Of Particulate Matter

Mylan Institutional LLC Initiates Voluntary Nationwide Recall Of Levoleucovorin Injection Due To The Presence Of Particulate Matter

ROCKFORD, Ill., March 18, 2019 /PRNewswire/ -- Mylan Institutional LLC is conducting a voluntary nationwide recall of two lots (see table below) of Levoleucovorin Injection, 250 mg/25 mL tothe consumer/user level.

SBP, Mylan Present Keys To Hurricane Maria Survivor In Welcome Home Party -- Courtesy Of $1M Pledge From The Mylan Charitable Foundation

SBP, Mylan Present Keys To Hurricane Maria Survivor In Welcome Home Party -- Courtesy Of $1M Pledge From The Mylan Charitable Foundation

Money to Aid Ongoing Recovery Efforts in Puerto Rico, Funding the Rebuild and Repair of at Least 100 Homes

Mylan To Present At Raymond James 40th Annual Institutional Investors Conference

Mylan To Present At Raymond James 40th Annual Institutional Investors Conference

HERTFORDSHIRE, England and PITTSBURGH, Feb. 28, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan Falls on Fourth-Quarter Earnings and Guidance Miss

Mylan Falls on Fourth-Quarter Earnings and Guidance Miss

Shares of Mylan tumble after the generic drugmaker misses Wall Street's fourth-quarter earnings and 2019 forecast expectations.

Mylan Reports Fourth Quarter And Full Year 2018 Results And Provides 2019 Guidance

Mylan Reports Fourth Quarter And Full Year 2018 Results And Provides 2019 Guidance

HERTFORDSHIRE, England and PITTSBURGH, Feb. 26, 2019 /PRNewswire/ --  Mylan N.

Elon Musk, Jerome Powell, Home Depot, AT&T, Shake Shack - 5 Things You Must Know

Elon Musk, Jerome Powell, Home Depot, AT&T, Shake Shack - 5 Things You Must Know

U.S. stock futures decline amid a series of geopolitical risks that trimmed risked appetite; Federal Reserve Chairman Jerome Powell will testify before a Senate committee on Tuesday; the SEC asks a judge to hold Tesla's Elon Musk in contempt of court; Home Depot, Macy's and Palo Alto Networks report earnings.

Mylan Launches Generic Suboxone® Sublingual Film To Treat Opioid Dependence

Mylan Launches Generic Suboxone® Sublingual Film To Treat Opioid Dependence

HERTFORDSHIRE, England and PITTSBURGH, Feb. 22, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan To Release 2018 Fourth Quarter And Full Year Results And 2019 Guidance On Feb. 26, 2019

Mylan To Release 2018 Fourth Quarter And Full Year Results And 2019 Guidance On Feb. 26, 2019

HERTFORDSHIRE, England, and PITTSBURGH, Feb. 11, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan Announces FDA Approval Of Wixela™ Inhub™ (fluticasone Propionate And Salmeterol Inhalation Powder, USP), First Generic Of ADVAIR DISKUS® (fluticasone Propionate And Salmeterol Inhalation Powder)

Mylan Announces FDA Approval Of Wixela™ Inhub™ (fluticasone Propionate And Salmeterol Inhalation Powder, USP), First Generic Of ADVAIR DISKUS® (fluticasone Propionate And Salmeterol Inhalation Powder)

Wixela™ Inhub™ is the first FDA-approved therapeutically equivalent generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or chronic obstructive pulmonary disease (COPD)

Heat Biologics Takes Beating After Pricing $12 Million Stock Offering

Heat Biologics Takes Beating After Pricing $12 Million Stock Offering

Heat Biologics Inc. nosedived after the Durham, North Carolina-based biopharmaceutical company filed for a share offering pricing expected to hit $12 million.

TheStreet Quant Rating: C- (Hold)